AAPL   398.10 (+3.76%)
MSFT   214.38 (+0.33%)
FB   247.46 (+0.98%)
GOOGL   1,566.60 (+1.79%)
AMZN   3,316.94 (+3.65%)
NVDA   427.11 (+1.89%)
BABA   262.45 (+0.55%)
TSLA   1,764.04 (+14.20%)
AMD   56.59 (+1.27%)
GILD   77.39 (+1.40%)
NFLX   563.25 (+2.65%)
BAC   23.93 (-0.37%)
BA   175.96 (-1.39%)
AAPL   398.10 (+3.76%)
MSFT   214.38 (+0.33%)
FB   247.46 (+0.98%)
GOOGL   1,566.60 (+1.79%)
AMZN   3,316.94 (+3.65%)
NVDA   427.11 (+1.89%)
BABA   262.45 (+0.55%)
TSLA   1,764.04 (+14.20%)
AMD   56.59 (+1.27%)
GILD   77.39 (+1.40%)
NFLX   563.25 (+2.65%)
BAC   23.93 (-0.37%)
BA   175.96 (-1.39%)
AAPL   398.10 (+3.76%)
MSFT   214.38 (+0.33%)
FB   247.46 (+0.98%)
GOOGL   1,566.60 (+1.79%)
AMZN   3,316.94 (+3.65%)
NVDA   427.11 (+1.89%)
BABA   262.45 (+0.55%)
TSLA   1,764.04 (+14.20%)
AMD   56.59 (+1.27%)
GILD   77.39 (+1.40%)
NFLX   563.25 (+2.65%)
BAC   23.93 (-0.37%)
BA   175.96 (-1.39%)
AAPL   398.10 (+3.76%)
MSFT   214.38 (+0.33%)
FB   247.46 (+0.98%)
GOOGL   1,566.60 (+1.79%)
AMZN   3,316.94 (+3.65%)
NVDA   427.11 (+1.89%)
BABA   262.45 (+0.55%)
TSLA   1,764.04 (+14.20%)
AMD   56.59 (+1.27%)
GILD   77.39 (+1.40%)
NFLX   563.25 (+2.65%)
BAC   23.93 (-0.37%)
BA   175.96 (-1.39%)
Log in

NASDAQ:AKTXAkari Therapeutics Stock Price, Forecast & News

$1.96
-0.02 (-1.01 %)
(As of 07/13/2020 10:56 AM ET)
Add
Compare
Today's Range
$1.96
Now: $1.96
$2.00
50-Day Range
$1.97
MA: $2.19
$2.61
52-Week Range
$0.87
Now: $1.96
$3.35
Volume220 shs
Average Volume458,339 shs
Market Capitalization$31.09 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.73
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its lead drug candidate is Coversin, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, and atypical hemolytic uremic syndrome. The company is based in New York, New York. Akari Therapeutics, Plc is a subsidiary of RPC Pharma Limited.
Read More
Akari Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKTX
CUSIPN/A
Phone646-350-0702

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.11) per share

Profitability

Net Income$-17,110,000.00

Miscellaneous

Employees17
Market Cap$31.09 million
Next Earnings Date9/3/2020 (Estimated)
OptionableNot Optionable

Receive AKTX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

Akari Therapeutics (NASDAQ:AKTX) Frequently Asked Questions

How has Akari Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Akari Therapeutics' stock was trading at $1.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AKTX stock has increased by 27.3% and is now trading at $1.96. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Akari Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akari Therapeutics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Akari Therapeutics.

When is Akari Therapeutics' next earnings date?

Akari Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Akari Therapeutics.

How were Akari Therapeutics' earnings last quarter?

Akari Therapeutics PLC (NASDAQ:AKTX) announced its quarterly earnings data on Friday, May, 29th. The biopharmaceutical company reported ($0.13) EPS for the quarter. View Akari Therapeutics' earnings history.

What price target have analysts set for AKTX?

1 equities research analysts have issued twelve-month price objectives for Akari Therapeutics' shares. Their forecasts range from $5.00 to $5.00. On average, they expect Akari Therapeutics' share price to reach $5.00 in the next year. This suggests a possible upside of 155.1% from the stock's current price. View analysts' price targets for Akari Therapeutics.

Has Akari Therapeutics been receiving favorable news coverage?

Media stories about AKTX stock have trended very negative recently, according to InfoTrie. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Akari Therapeutics earned a coverage optimism score of -3.2 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news about Akari Therapeutics.

Who are some of Akari Therapeutics' key competitors?

What other stocks do shareholders of Akari Therapeutics own?

Who are Akari Therapeutics' key executives?

Akari Therapeutics' management team includes the following people:
  • Dr. Ray Prudo, Exec. Chairman (Age 74)
  • Mr. Clive Richardson, COO, Director & Interim CEO (Age 54)
  • Mr. Dov Elefant, Chief Financial Officer (Age 52)
  • Dr. Miles Nunn, Chief Scientific Officer

What is Akari Therapeutics' stock symbol?

Akari Therapeutics trades on the NASDAQ under the ticker symbol "AKTX."

How do I buy shares of Akari Therapeutics?

Shares of AKTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akari Therapeutics' stock price today?

One share of AKTX stock can currently be purchased for approximately $1.96.

How big of a company is Akari Therapeutics?

Akari Therapeutics has a market capitalization of $31.09 million. The biopharmaceutical company earns $-17,110,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Akari Therapeutics employs 17 workers across the globe.

What is Akari Therapeutics' official website?

The official website for Akari Therapeutics is www.akaritx.com.

How can I contact Akari Therapeutics?

Akari Therapeutics' mailing address is 75/76 WIMPOLE STREET, LONDON X0, W1G 9RT. The biopharmaceutical company can be reached via phone at 646-350-0702 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.